Mode
Home
Conditions Medications Drug Pipeline Weekly Digests Questions
Text Size
Log in / Sign up
Home › Questions › Rheumatology

How does the mortality risk for microscopic polyangiitis compare to granulomatosis with polyangiitis?

high confidence  ·  Last reviewed May 23, 2026

Microscopic polyangiitis (MPA) and granulomatosis with polyangiitis (GPA) are both types of ANCA-associated vasculitis (AAV), but they have different mortality risks. Research consistently shows that MPA is associated with a higher risk of death compared to GPA. For example, a large Japanese cohort study found that MPA patients had a 2.5 times higher risk of death than GPA patients 6. Another study reported that five-year survival for MPA was 67.6%, while GPA had better outcomes 3. Understanding these differences can help doctors tailor monitoring and treatment for each condition.

What the research says

Multiple studies confirm that MPA carries a higher mortality risk than GPA. A 2025 Japanese multicenter study of 729 patients found that phenotype-based classification (MPA vs. GPA) was strongly linked to mortality: MPA had a hazard ratio (HR) of 2.53 for death compared to GPA 6. This means MPA patients were about 2.5 times more likely to die during follow-up. Another Japanese cohort reported that MPA had the poorest prognosis among AAV subtypes, with a five-year overall survival of only 67.6% 3. In contrast, GPA patients in that study had better survival rates.

A large US retrospective cohort also found that both MPA and GPA had higher mortality than matched controls, but the absolute mortality rate was higher in MPA (25.85%) than in GPA (17.87%) 2. However, the hazard ratios for death were similar (HR 3.01 for both) after adjusting for differences, suggesting that while both diseases increase mortality risk, MPA patients may have a higher baseline risk 2.

Some studies highlight that the difference in mortality may be related to clinical features. For instance, MPA is more often associated with severe kidney involvement, which can worsen outcomes 6. Additionally, a study from Germany noted that MPO-ANCA-positive GPA (a subtype) often had milder disease than MPA, which may contribute to better survival in GPA overall 5.

What to ask your doctor

  • Given that MPA has a higher mortality risk than GPA, what specific monitoring or treatment plan do you recommend for my condition?
  • Are there any additional tests (like kidney function or cardiovascular assessments) that I should have regularly to manage my risk?
  • How does my ANCA type (MPO or PR3) affect my prognosis and treatment options?
  • What lifestyle changes or medications can help reduce my risk of complications, such as infections or cardiovascular events?
  • Should I be referred to a specialist (e.g., rheumatologist, nephrologist) for more targeted care?

This question is drawn from common patient questions about Rheumatology and answered using cited medical research. We do not provide individualized advice.